+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market - Global Forecast 2025-2030- Product Image
Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market - Global Forecast 2025-2030- Product Image
Sale

Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6131520
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Human granulocyte/macrophage colony-stimulating factor (GM-CSF) injections are central to supportive therapies in oncology, hematology, and emergency preparedness, continually evolving through scientific innovation and shifting market dynamics. The market is adapting to new standards in both product development and global distribution, presenting significant opportunities for industry leaders to optimize strategies and capture value.

Market Snapshot: GM-CSF Injection Therapeutics

The human GM-CSF injection market reflects steady expansion, powered by breakthrough recombinant technology, improved manufacturing safety, and diversification of end-use settings. Since its late 20th-century discovery, GM-CSF has transformed patient care by reducing infection risk and enabling more efficient recovery after intensive treatments. Industry stakeholders—including researchers, clinicians, and manufacturers—are advancing therapies to address a wide array of clinical, operational, and economic requirements.

Scope & Segmentation

  • Product Types: Animal-sourced derivatives from bovine and porcine origins; recombinant formulations using E. coli or yeast hosts
  • Application Areas: Cancer therapy protocols; radiation exposure countermeasures; support for stem cell transplant recovery
  • End-User Environments: Hospitals, specialty clinics, hospice care, and home-based patient administration
  • Distribution Channels: Hospital pharmacies, online sales via manufacturer and third-party platforms, and retail outlets covering both chains and independents
  • Dosage Formats: Prefilled syringes (single-use, multi-dose) and vials (single-dose, multi-dose) tailored to clinical and homecare demands
  • Route of Administration: Intravenous (both professional and self-injection) and subcutaneous options for greater flexibility
  • Regions Covered: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East and Africa (notable countries include United Kingdom, Germany, France, among others), Asia-Pacific (including China, India, Japan, Australia, Southeast Asia, and more)
  • Leading Companies Monitored: Partner Therapeutics, Inc.; Chugai Pharmaceutical Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Zhejiang Puluo Biological Medicine Co., Ltd.; Shenzhen Neptunus Biotech Co., Ltd.

Key Takeaways for Decision-Makers

  • Rapid advances in recombinant and biosimilar GM-CSF development minimize reliance on animal-derived sources, enhancing scalability and safety profiles.
  • Innovative delivery formats, such as prefilled syringes and subcutaneous presentations, are broadening adoption outside traditional hospital settings and improving patient adherence.
  • Regulatory authorities worldwide emphasize rigorous assessment protocols for biosimilars, driving manufacturers to prioritize comparability, stability, and patient-centric features.
  • Regional market differences—shaped by reimbursement strategies, policy frameworks, and infrastructure—necessitate localized commercial strategies and agile supply chain solutions.
  • Rising competition from biosimilar entrants is elevating the importance of value-added services, including digital engagement, adherence monitoring, and patient support initiatives.
  • Strategic partnerships and alliances between innovators, research organizations, and regional players help reduce development timelines and facilitate global market reach.

Tariff Impact on Supply Chain and Manufacturing

United States tariff adjustments in 2025 have increased costs for key supplies—such as chromatography resins and single-use bioprocessing equipment—impacting GM-CSF injection production overhead. Manufacturers and contract partners are responding with supply chain diversification, bulk purchasing, and local warehousing to stabilize costs and mitigate disruptions. Strategic negotiations with payers and healthcare systems are increasingly influenced by these evolving cost structures.

Methodology & Data Sources

This report integrates secondary research from peer-reviewed literature, regulatory updates, and company reports, augmented by structured interviews with global executives and clinical experts. Quantitative analysis utilizes proprietary databases and real-world utilization data, with validation from biotechnology, regulatory, and procurement thought leaders to ensure accuracy and practical relevance.

Why This Report Matters

  • Enables senior leaders to identify high-impact innovation, regulatory trends, and partnership opportunities within the GM-CSF injection market.
  • Supports informed resource allocation and regional strategy development aligned to market maturity and reimbursement variability.
  • Provides an action-oriented foundation for optimizing product portfolios and responding proactively to competitive and policy changes.

Conclusion

The human granulocyte/macrophage colony-stimulating factor market is distinguished by scientific advances, strategic collaborations, and adaptive approaches to evolving operational challenges. Success hinges on ongoing innovation, responsible supply chain management, and aligned stakeholder engagement to unlock sustainable growth and clinical value.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of biosimilar GM-CSF products offering cost-effective treatment alternatives
5.2. Advances in pegylated GM-CSF formulations extending half-life and reducing dosing frequency
5.3. Rising adoption of GM-CSF injections in immuno-oncology regimens to boost patient outcomes
5.4. Expansion of outpatient infusion services to accommodate growing GM-CSF therapy demand in neutropenia management
5.5. Ongoing clinical trials evaluating GM-CSF combinations for autoimmune and inflammatory disease indications
5.6. Regulatory approvals of next-generation GM-CSF biologics fuelling competitive pipeline launches
5.7. Manufacturers deploying digital adherence tools to enhance patient monitoring during GM-CSF therapy
5.8. Strategic alliances between biotechs and CMOs to scale up GM-CSF manufacturing capacity amid supply constraints
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market, by Product Type
8.1. Introduction
8.2. Animal Derived
8.2.1. Bovine Source
8.2.2. Porcine Source
8.3. Recombinant
8.3.1. E Coli Derived
8.3.2. Yeast Derived
9. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market, by Application
9.1. Introduction
9.2. Cancer Treatment
9.3. Radiation Countermeasure
9.4. Stem Cell Transplant Support
10. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Homecare Settings
10.3.1. Hospice
10.3.2. Patient Homes
10.4. Hospitals
11. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.3.1. Manufacturer Platforms
11.3.2. Third Party ERetailers
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market, by Dosage Form
12.1. Introduction
12.2. Prefilled Syringes
12.2.1. Multi Dose
12.2.2. Single Use
12.3. Vials
12.3.1. Multi Dose
12.3.2. Single Dose
13. Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market, by Route Of Administration
13.1. Introduction
13.2. Intravenous
13.2.1. Healthcare Professional Administration
13.2.2. Self Administration
13.3. Subcutaneous
13.3.1. Healthcare Professional Administration
13.3.2. Self Administration
14. Americas Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Human Granulocyte/Macrophage Colony-stimulating Factor for Injection Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Partner Therapeutics, Inc.
17.3.2. Chugai Pharmaceutical Co., Ltd.
17.3.3. Dainippon Sumitomo Pharma Co., Ltd.
17.3.4. Zhejiang Puluo Biological Medicine Co., Ltd.
17.3.5. Shenzhen Neptunus Biotech Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET: RESEARCHAI
FIGURE 28. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 29. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET: RESEARCHCONTACTS
FIGURE 30. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY BOVINE SOURCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY BOVINE SOURCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PORCINE SOURCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PORCINE SOURCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY E COLI DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY E COLI DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY YEAST DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY YEAST DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RADIATION COUNTERMEASURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RADIATION COUNTERMEASURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY STEM CELL TRANSPLANT SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY STEM CELL TRANSPLANT SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOSPICE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOSPICE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PATIENT HOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PATIENT HOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY MANUFACTURER PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY MANUFACTURER PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY THIRD PARTY ERETAILERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY THIRD PARTY ERETAILERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SINGLE USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HEALTHCARE PROFESSIONAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HEALTHCARE PROFESSIONAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HEALTHCARE PROFESSIONAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HEALTHCARE PROFESSIONAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 169. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 170. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 171. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2018-2024 (USD MILLION)
TABLE 172. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2025-2030 (USD MILLION)
TABLE 173. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 174. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 175. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 180. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 181. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 184. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 185. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 188. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 189. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 190. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 191. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 192. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 193. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 196. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 197. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 198. CANADA HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2018-2024 (USD MILLION)
TABLE 202. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ANIMAL DERIVED, 2025-2030 (USD MILLION)
TABLE 203. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 204. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 205. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 210. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY HOMECARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 211. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 214. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 215. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 216. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, 2025-2030 (USD MILLION)
TABLE 221. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. MEXICO HUMAN GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Human Granulocyte/Macrophage Colony-stimulating Factor for Injection market report include:
  • Partner Therapeutics, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Dainippon Sumitomo Pharma Co., Ltd.
  • Zhejiang Puluo Biological Medicine Co., Ltd.
  • Shenzhen Neptunus Biotech Co., Ltd.

Related Topics

Related Reports

Granulocyte Macrophage Colony Stimulating Factor Market - Global Forecast 2025-2030 - Product Image

Granulocyte Macrophage Colony Stimulating Factor Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Pegfilgrastim Injection Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Pegfilgrastim Injection Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Recombinant Human Follicle Stimulating Hormone Injection Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Recombinant Human Follicle Stimulating Hormone Injection Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Recombinant Human Interleukin-2 for Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Recombinant Human Interleukin-2 for Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From
Prefilled Human Growth Hormone Injection Market - Global Forecast 2025-2030 - Product Image

Prefilled Human Growth Hormone Injection Market - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.